Acadia Pharma (ACAD) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $29.01 +2.73%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.65), in-line with the analyst estimate of ($0.65). Revenue for the quarter came in at $11.96 million versus the consensus estimate of $9.05 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
